Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT06409637 2024-05-10

FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation

Phase 1/2 Not yet recruiting

62 enrolled

Gastrointestinal

Liver Neoplasms

NCT04444167 2024-04-25

A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma

Phase 1/2 Completed

59 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT05842317 2024-02-09

Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC

Phase 1/2 Unknown

60 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT03867370 2023-11-29

Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma

Phase 1/2 Terminated

40 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT04443309 2023-03-29

Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC

Phase 1/2 Unknown

53 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT04911959 2023-02-06

Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCC

Phase 1/2 Unknown

50 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT05327582 2022-04-14

An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC

Phase 1/2 Unknown

65 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Pancreatic Neoplasms

NCT00946153 2019-02-01

Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)

Phase 1/2 Completed

66 enrolled 18 charts

Gastrointestinal

Carcinoma, Carcinoma, Hepatocellular

Clinical Trials

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

MK-3475-06B

Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention

A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer

Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant Ascites

A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors

A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations

Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs Therapy

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation

A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma

Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC

Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma

Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC

Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCC

An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC

Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)